ONE-WAYOngoing theme · still written in the latest filings

Development of F528 as a COPD treatment

A drug development program for F528, a novel anti-inflammatory agent that suppresses multiple inflammatory cytokines, aimed at slowing the progression of chronic obstructive pulmonary disease (COPD), including the filing of IND applications in China and the United States.

Companies1How many companies write about this.

Threads1One company can carry more than one thread here.

PeriodFY2024-Q1 →Still being written about.

Directionhelps1 helps · 0 hurts · 0 flat